Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,251,983 papers from all fields of science
Search
Sign In
Create Free Account
1 ML palivizumab 100 MG/ML Injection [Synagis]
Known as:
PALIVIZUMAB 100 mg in 1 mL INTRAMUSCULAR INJECTION, SOLUTION [Synagis]
, Synagis 100 MG in 1 ML Injection
, Synagis 100 MG per 1 ML Injection
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
8 relations
Broader (2)
1 ML palivizumab 100 MG/ML Injection
palivizumab Injection [Synagis]
Chloride Ion
Glycine
Histidine
Injection
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Intérêt microbiologique du palivizumab chez les nourrissons atteints de mucoviscidose : étude rétrospective, multicentrique, cas-témoins
Clélia Buchs
,
M.-L. Dalphin
,
S. Sanchez
,
M. Perceval
,
B. Kasaï
,
P. Reix
2017
Corpus ID: 80066643
2014
2014
138: Respiratory Illness and Respiratory Syncytial Virus Hospitalizations in Infants with Congenital Airway Anomalies in the Canadian Registry of Synagis® Following Prophylaxis (2005–2013)
B. Paes
,
A. Li
,
I. Mitchell
,
K. Lanctôt
2014
Corpus ID: 80143902
2013
2013
Rsv Hospitalization In Infants With Neuromuscular Disease In The Canadian Registry Of Synagis® (Caress) Following Prophylaxis (2005-2012)
T. Harimoto
,
B. Paes
,
I. Mitchell
,
Abby Li
,
K. Lanctôt
2013
Corpus ID: 75146105
Review
2012
Review
2012
Targeting RSV with vaccines and small molecule drugs.
Heather M. Costello
,
W. Ray
,
S. Chaiwatpongsakorn
,
M. Peeples
Infectious disorders drug targets
2012
Corpus ID: 2176096
Respiratory syncytial virus (RSV) is the most significant cause of pediatric respiratory infections. Palivizumab (Synagis®), a…
Expand
2012
2012
263 RSV Hospitalization in Cystic Fibrosis in the Canadian Registry of Synagis® (Caress) following Prophylaxis (2005–2011)
B. Paes
,
Abby Li
,
I. Mitchell
,
K. Lanctôt
Archives of Disease in Childhood
2012
Corpus ID: 74857660
Background and Aims The Canadian Registry of Synagis® (CARESS) tracks palivizumab utilization and respiratory syncytial virus…
Expand
2012
2012
861 RSV Hospitalization in Infants with Neuromuscular Disease in the Canadian Registry of Synagis® (Caress) Following Prophylaxis (2005–2011)
B. Paes
,
Abby Li
,
I. Mitchell
,
K. Lanctôt
Archives of Disease in Childhood
2012
Corpus ID: 76237252
Background and Aims The Canadian Registry of Synagis® (CARESS) tracks palivizumab use and respiratory outcomes in high-risk…
Expand
Review
2011
Review
2011
Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup…
D. Wang
,
S. Bayliss
,
C. Meads
Health technology assessment
2011
Corpus ID: 46534002
BACKGROUND Respiratory syncytial virus (RSV) is a seasonal infectious disease, with epidemics occurring annually from October to…
Expand
2004
2004
Prévention des infections à VRS par le palivizumab (Synagis®) chez les enfants atteints de cardiopathie congénitale. Recommandations de la Filiale de Cardiologie Pédiatrique de la Société Française…
A. Chantepie
2004
Corpus ID: 71240970
2004
2004
Quando indicar o palivizumab (Synagis®) na profilaxia da infecção do trato respiratório inferior pelo vírus sincicial respiratório?
R. A. Vieira
,
E. M. A. Diniz
,
F. Vaz
2004
Corpus ID: 72801406
Highly Cited
1998
Highly Cited
1998
Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia
X. Sáez-Llorens
,
E. Castaño
,
+5 authors
E. Connor
1998
Corpus ID: 71920687
Background.Respiratory syncytial virus (RSV) is the leading cause of lower respiratory disease in infants and children. MEDI-493…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE